All In Biotech

Drug Trial Radar · NCT06899126

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 686 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

686

Planned (sponsor's estimate)

Start

Oct 24, 2025

Primary completion

Apr 24, 2030

Study completion Nov 24, 2032

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Mar 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W)

  • pembrolizumabDrug

    pembrolizumab will be administered at a dose of 200 mg IV Q3W

  • PemetrexedDrug

    Pemetrexed will be administered at a dose of 500 mg/m\^2 IV Q3W

  • Platinum ChemotherapyDrug

    One of the following two will be administered in Arm B: Cisplatin at a dose of 75 mg/m\^2 IV or carboplatin AUC at a dose of 5 mg/mL/min IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival by Blinded Independent Central ReviewTime frame: From date of randomization to the date of radiographic disease progression or death due to any cause, up to approximately 54 months

Locations

247 sites in 24 countries. Site status is shown where the registry gives one.

  • Alaska Oncology & Hematology, LLC

    Anchorage, Alaska · Recruiting

  • Orange Coast Memorial Medical Center Fountain Valley

    Fountain Valley, California · Recruiting

  • California Research Institute

    Los Angeles, California · Recruiting

  • Los Angeles Cancer Network (LACN)

    Los Angeles, California · Recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Bay Pines VA Healthcare System

    Bay Pines, Florida · Recruiting

  • Lynn Cancer Institute Center

    Boca Raton, Florida · Recruiting

  • Holy Cross Hospital

    Fort Lauderdale, Florida · Recruiting

  • Mid-Florida Hematology & Oncology Centers, P.A.

    Orange City, Florida · Recruiting

  • BRCR Global Plantation

    Plantation, Florida · Recruiting

  • Cleveland Clinic Florida - Weston

    Weston, Florida · Recruiting

  • Piedmont Cancer Institute OneOncology

    Atlanta, Georgia · Recruiting

  • The Queens Medical Center

    Honolulu, Hawaii · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Logan Health Research

    Kalispell, Montana · Recruiting

  • Renown Regional Medical Center

    Reno, Nevada · Recruiting

  • Clinical Research Alliance

    Westbury, New York · Recruiting

  • FirstHealth Cancer Center

    Pinehurst, North Carolina · Recruiting

  • Carolina Cancer Research Center

    Wilson, North Carolina · Recruiting

  • Gabrail Cancer Center

    Canton, Ohio · Recruiting

  • St. Charles Health System

    Bend, Oregon · Recruiting

  • University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Lumi Research

    Kingwood, Texas · Recruiting

  • Summit Cancer Treatment Center

    Spokane, Washington · Recruiting

  • CINME - Centro De Investigaciones Metabolicas

    Buenos Aires, Argentina · Recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Instituto Argentino de Diagnostico y Tratamiento

    Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Metabolicas (IDIM)

    Buenos Aires, Argentina · Recruiting

  • Centro de Investigaciones Medicas y Desarrollo LC SRL (LC Investigacion)

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • Instituto de Investigaciones Clinicas Cordoba S.A.

    Córdoba, Argentina · Recruiting

  • Centro de Investigacion Pergamino SA

    Pergamino, Argentina · Recruiting

  • Hospital Universitario Austral

    Pilar, Argentina · Recruiting

  • Sanatorio Britanico S.A.

    Rosario, Argentina · Recruiting

  • Instituto de Oncologia de Rosario

    Rosario, Argentina · Recruiting

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina · Recruiting

  • Sanatorio Parque S.A.

    Rosario, Argentina · Recruiting

  • Instituto San Marcos

    San Juan, Argentina · Recruiting

  • UZA

    Edegem, Belgium · Recruiting

Showing 40 of 247 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.